



**CONDENSED INTERIM FINANCIAL STATEMENTS**

(UNAUDITED - PREPARED BY MANAGEMENT)

(EXPRESSED IN CANADIAN DOLLARS)

**FOR THE THREE AND SIX MONTH PERIOD ENDED OCTOBER 31, 2016**

**VALENS GROWORKS CORP.**  
(Formerly Genovation Capital Corp.)

**NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED  
FINANCIAL STATEMENTS**

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the condensed interim consolidated financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of Valens Groworks Corp. ("the Company") have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

**VALENS GROWWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Condensed Interim Statement of Financial Position  
(Unaudited-Expressed in Canadian Dollars)

	Notes	October 31, 2016 \$	April 30, 2016 \$
<b>ASSETS</b>			
<b>Current</b>			
Cash and cash equivalents		8,912	70,720
Receivable		88,275	65,153
Prepaid expenses		600	-
Investment in MKHS, LLC	4	2,329,408	1,907,293
		<u>2,427,195</u>	<u>2,043,166</u>
Equipment	5	2,591	2,222
		<u>2,429,786</u>	<u>2,045,388</u>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>			
<b>Current</b>			
Accounts payable and accrued liabilities	7	1,435,636	827,583
Convertible debenture	8	371,547	618,261
		<u>1,807,183</u>	<u>1,445,844</u>
<b>Shareholders' equity</b>			
Share capital	6	6,686,003	6,418,003
Convertible debentures-equity component	8	28,871	50,157
Contributed surplus	6	996,285	989,635
Deficit		(7,088,556)	(6,858,251)
		<u>622,603</u>	<u>599,544</u>
		<u>2,429,786</u>	<u>2,045,388</u>

**Nature and continuance of operations (Note 1)**

**Contingent liability (Note 11)**

**Subsequent events (Note 12)**

**Approved on behalf of the Board on December 19, 2016**

Signed

Signed

"Robert van Santen"  
Director

"John Binder"  
Director

The accompanying notes are an integral part of these condensed interim consolidated financial statements

**VALENS GROWWORKS CORP.**

(Formerly Genovation Capital Corp.)

Condensed Interim Statement of Comprehensive Loss

(Unaudited-Expressed in Canadian Dollars)

For the six months ended October 31

	Note	For the three months ended		For the six months ended	
		2016	October 31,	2016	October 31,
		\$	\$	\$	\$
<b>General and Administrative expenses</b>					
Consulting fees		19,762	15,000	34,763	30,000
Depreciation	5	191	360	381	720
Insurance		-	1,660	-	4,150
Interest and bank charges		625	950	1,038	4,220
Management fees	7	48,750	50,001	97,500	97,500
Office, rent and miscellaneous		12,376	11,323	23,652	19,879
Professional fees (recovery)		26,594	3,265	28,494	(5,634)
Share based compensation		1,322	-	6,650	3,119
Telephone		56	1,129	3,046	2,322
Travel and business development		8,589	10,092	18,652	16,584
Transfer agent and filing fees		5,622	6,018	27,018	11,373
		123,887	99,798	241,194	184,233
<b>Net loss before other items</b>		(123,887)	(99,798)	(241,194)	(184,233)
<b>Other items</b>					
Other income		-	1	20,000	60,102
Foreign exchange gain (loss)		4	45	(9,111)	194
		4	46	10,889	60,296
<b>Loss and comprehensive loss for the period</b>		(123,883)	(99,752)	(230,305)	(123,937)
<b>Basic and diluted loss per share</b>		(0.01)	(0.02)	(0.02)	(0.03)
<b>Weighted average number of shares outstanding</b>		11,318,501	5,430,820	11,124,298	4,793,468

The accompanying notes are an integral part of these condensed interim consolidated financial statements

**VALENS GROWWORKS CORP.**

(Formerly Genovation Capital Corp.)

Condensed Interim Statement of Changes in Shareholders' Equity

(Unaudited-Expressed in Canadian Dollars)

	<b>Share Capital</b>		<b>Contributed Surplus</b>	<b>Convertible debt equity portion</b>	<b>Deficit</b>	<b>Total</b>
	<b>Number</b>	<b>Amount</b>				
		<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
<b>Balance, April 30, 2015</b>	<b>3,013,006</b>	5,125,795	<b>936,485</b>	-	<b>(6,067,347)</b>	<b>(5,067)</b>
Shares issued for cash	3,060,177	529,860	-	-	-	529,860
Share based compensation	-	-	3,119	-	-	3,119
Net loss for the period	-	-	-	-	(123,937)	(123,937)
<b>Balance, October 31, 2015</b>	<b>6,073,183</b>	<b>5,655,655</b>	<b>939,604</b>	-	<b>(6,191,284)</b>	<b>403,975</b>
Shares issued for cash	1,608,473	505,766	-	-	-	505,766
Share issued to settle debt	1,403,512	256,582	-	-	-	256,582
Convertible debentures-equity component	-	-	-	50,157	-	50,157
Share based compensation	-	-	50,031	-	-	50,031
Net loss for the period	-	-	-	-	(666,967)	(666,967)
<b>Balance, April 30, 2016</b>	<b>9,085,168</b>	<b>6,418,003</b>	<b>989,635</b>	<b>50,157</b>	<b>(6,858,251)</b>	599,544
Shares issued on conversion of debentures	2,233,333	268,000	-	-	-	268,000
Convertible debentures-equity component	-	-	-	(21,286)	-	(21,286)
Share based compensation	-	-	6,650	-	-	6,650
Net loss for the period	-	-	-	-	(230,305)	(230,305)
<b>Balance, October 31, 2016</b>	<b>11,318,501</b>	<b>6,686,003</b>	<b>996,285</b>	<b>28,871</b>	<b>(7,088,556)</b>	<b>622,603</b>

The accompanying notes are an integral part of these condensed interim consolidated financial statements

**VALENS GROWWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Condensed Interim Statement of Cash Flows  
(Unaudited-Expressed in Canadian Dollars)  
For the six months ended October 31

	<b>Six Months Ended October 31, 2016</b>	<b>Six Months Ended October 31, 2015</b>
	\$	\$
<b>OPERATING ACTIVITIES</b>		
Loss for the period	(230,305)	(123,937)
Adjustment for non-cash items:		
Depreciation	381	719
Share based compensation	6,650	3,119
	<u>(223,274)</u>	<u>(120,099)</u>
Working capital adjustments		
Trade and other receivables	(23,122)	(1,270)
Due from related parties	-	(8,145)
Prepaid expenses	(600)	-
Advances receivable	-	(13,351)
Accounts payable and accrued liabilities	608,053	(181,827)
Due to related company	-	(27,149)
Promissory note payable	-	(132,160)
	<u>361,057</u>	<u>(484,001)</u>
<b>INVESTING ACTIVITIES</b>		
Equipment	(750)	-
Investment in MKHS, LLC	(422,115)	(134,000)
	<u>(422,865)</u>	<u>(134,000)</u>
<b>FINANCING ACTIVITIES</b>		
Proceeds from share issuance	-	529,860
Subscription received in advance	-	134,000
	<u>-</u>	<u>663,860</u>
<b>NET CHANGE IN CASH AND CASH EQUIVALENTS</b>	<b>(61,808)</b>	<b>45,859</b>
<b>Cash and cash equivalents, beginning of period</b>	<b>70,720</b>	<b>10,539</b>
<b>Cash and cash equivalents, end of period</b>	<b>8,912</b>	<b>56,398</b>
<b>Supplemental disclosure with respect to cash flows:</b>		
Share issuance costs accrued through accounts payable and accrued liabilities	-	-
Accounts payable and accrued liabilities settled through the issuance of common shares	-	69,250
Promissory note payable settled through the issuance of common shares	-	147,360
Convertible debenture exercised through the issuance of common shares	268,000	-

The accompanying notes are an integral part of these condensed interim consolidated financial statements

## **VALENS GROWORKS CORP.**

(Formerly Genovation Capital Corp.)

Notes to the Condensed Interim Statements

For the Six Months Ended October 31, 2016

(Unaudited-Expressed in Canadian Dollars)

---

### **1. NATURE AND CONTINUANCE OF OPERATIONS**

Valens GroWorks Corp. (formerly Genovation Capital Corp.) (the “Company”) was incorporated under the laws of British Columbia on January 14, 1981. On November 2, 2016 the Company completed the acquisition of all the issued and outstanding shares of Valens Agritech Ltd. (“Valens”) by way of a share exchange agreement dated October 31, 2016, thereby transitioning to the life sciences sector. On November 24, 2016 the Company completed its corporate name change to Valens GroWorks Corp. The Company’s common shares trade under the trading symbol “VGW” on the Canadian Securities Exchange (“CSE”).

The address of the Company’s registered and records office and head office address is 14<sup>th</sup> Floor, 1040 West Georgia Street, Vancouver, British Columbia, Canada V6E 4H1.

The financial statements were prepared on a going concern basis in accordance with International Financial Reporting Standards (“IFRS”), with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of operations rather than through a process of forced liquidation.

The Company has incurred losses since its inception and had an accumulated deficit of \$7,088,556 as at October 31, 2016. The Company’s ability to continue as a going concern is dependent upon the ability of the Company to obtain financing and generate positive cash flows from its operations. Management of the Company does not expect that cash flows for the Company’s operations will be sufficient to cover its operating requirements, financial commitments and business development priorities during the next twelve months. Accordingly, the Company expects that it will need to obtain further financing in the form of debt, equity or a combination thereof for the next twelve months. There can be no assurance that additional funding will be available to the Company, or, if available, that this funding will be on acceptable terms. These material uncertainties may cast significant doubt about the Company’s ability to continue as a going concern.

On July 15, 2016 the Company completed a consolidation of its share capital on a 3:1 basis approved by shareholders on April 29, 2016. All share and per share amounts have been restated to reflect the consolidation.

The financial statements of the Company for the period ended October 31, 2016 were authorized for issue by the Board of Directors on December 19, 2016.

### **2. BASIS OF PREPARATION**

#### **Statement of compliance**

These financial statements, including comparatives, have been prepared in accordance with IFRS as issued by the International Accounting Standards Board (“IASB”) and interpretations issued by the International Financial Reporting Interpretations Committee (“IFRIC”).

#### **Basis of preparation**

These financial statements have been prepared on the accrual basis of accounting except for cash flow information, and on a historical cost basis except for certain financial assets measured at fair value. The financial statements are presented in Canadian Dollars, which is also the Company’s functional currency, unless otherwise indicated.

#### **Critical accounting estimates**

The preparation of these financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities and contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period.

**VALENS GROWWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Notes to the Condensed Interim Statements  
For the Six Months Ended October 31, 2016  
(Unaudited-Expressed in Canadian Dollars)

---

**2. BASIS OF PREPARATION-continued**

**Critical accounting estimates-continued**

Estimates and assumptions are continuously evaluated and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. However, actual outcomes can differ from these estimates.

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the end of the reporting period, that could result in a material adjustment to the carrying amounts of assets and liabilities in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

- i) The inputs used in calculating the fair value for share-based compensation expense included in profit or loss.
- ii) The valuation of shares issued in non-cash transactions, including the settlement of debt. Generally, the valuation of non-cash transactions is based on the value of the goods or services received. When non-cash transactions are entered into with employees and those providing similar services, the non-cash transactions are measured at the fair value of the consideration given up using market prices.
- iii) The treatment of accounts payable and accrued liabilities written off through the statements of comprehensive loss requires certain management judgments. Management believes that the related vendors will not pursue payment from the Company or its former subsidiary. Further, these accounts payable relate to operations in a geographical segment the Company is no longer active in.
- iv) Going concern presentation of the financial statements which assumes that the Company will continue in operations for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due.

**3. SIGNIFICANT ACCOUNTING POLICIES**

**Basis of consolidation**

These financial statements include the financial statements of the Company. A subsidiary is included in the financial statements from the date control commences until the date control ceases. Control exists when the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. A former subsidiary is included in the financial statements from the date control commenced until March 11, 2015 when control ceased. All intra-company transactions, balances, income and expenses were eliminated in full on consolidation.

**Functional and presentation currency**

The functional currency of the Company (and its former subsidiary) is the Canadian dollar as this is the principal currency of the economic environment in which they operate. The Canadian dollar is also the Company's presentation currency. Transactions in foreign currencies are initially recorded in the Company's functional currency at the exchange rate at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency rate of exchange ruling at the end of each reporting period. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when fair value is determined. All gains and losses on translation of these foreign currency transactions are included in profit or loss.



**VALENS GROWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Notes to the Condensed Interim Statements  
For the Six Months Ended October 31, 2016  
(Unaudited-Expressed in Canadian Dollars)

---

**3. SIGNIFICANT ACCOUNTING POLICIES-continued**

**Cash and cash equivalents**

Cash and cash equivalents in the statement of financial position are comprised of cash and short-term deposits held at major financial institutions, which are readily convertible into known amounts of cash. The Company's cash and cash equivalents are invested in business and savings accounts which are available on demand by the Company for its operations.

Cash and cash equivalents consist of:

	October 31, 2016	April 30, 2016
Cash	\$ 3,162	\$ 64,970
Term deposits	5,750	5,750
<b>Total</b>	<b>\$ 8,912</b>	<b>\$ 70,720</b>

**Financial instruments**

i. Financial assets

The Company classifies its financial assets into one of the following categories as follows:

*Fair value through profit or loss* - This category comprises derivatives and financial assets acquired principally for the purpose of selling or repurchasing in the near term. They are carried at fair value with changes in fair value recognized in profit or loss.

*Loans and receivables* - These assets are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are carried at amortized cost using the effective interest method less any provision for impairment.

*Held-to-maturity investments* - These assets are non-derivative financial assets with fixed or determinable payments and fixed maturities that the Company's management has the positive intention and ability to hold to maturity. These assets are measured at amortized cost using the effective interest method less any provision for impairment.

*Available-for-sale* - Non-derivative financial assets not included in the above categories are classified as available-for-sale. They are carried at fair value with changes in fair value recognized in other comprehensive income (loss). Where a decline in the fair value of an available-for-sale financial asset constitutes objective evidence of impairment, the amount of the loss is removed from accumulated other comprehensive income (loss) and recognized in profit or loss.

All financial assets except those measured at fair value through profit or loss are subject to review for impairment at least at each reporting date. Financial assets are impaired when there is objective evidence of impairment as a result of one or more events that have occurred after initial recognition of the asset and that event has an impact on the estimated future cash flows of the financial asset or the group of financial assets.

ii. Financial liabilities

The Company classifies its financial liabilities into one of two categories as follows:

*Fair value through profit or loss* - This category comprises derivatives and financial liabilities incurred principally for the purpose of selling or repurchasing in the near term. They are carried at fair value with changes in fair value recognized in profit or loss.

**VALENS GROWWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Notes to the Condensed Interim Statements  
For the Six Months Ended October 31, 2016  
(Unaudited-Expressed in Canadian Dollars)

---

**3. SIGNIFICANT ACCOUNTING POLICIES-continued**

**Financial instruments-continued**

*Other financial liabilities* - This category consists of liabilities carried at amortized cost using the effective interest method.

The Company has classified its cash and cash equivalents as fair value through profit and loss, its investment in MKHS, LLC as available-for-sale, its receivables and advance receivable as loans and receivables and its accounts payable and accrued liabilities, promissory note payable and convertible debentures as other financial liabilities.

**Equipment**

Equipment is stated at historical cost less accumulated depreciation and accumulated impairment losses.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to the statement of income and comprehensive income during the financial period in which they are incurred.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized in profit or loss.

Depreciation is calculated using a declining balance method to write off the cost of the assets. The depreciation rates applicable to each category of property and equipment are as follows:

Computer equipment	55% Declining balance
Office equipment	20% Declining balance

**Impairment of non-financial assets**

At the end of each reporting period, the carrying amounts of the Company's assets are reviewed to determine whether there is any indication that those assets are impaired. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. The recoverable amount is the higher of fair value less costs to sell and value in use. Fair value is determined as the amount that would be obtained from the sale of the asset in an arm's length transaction between knowledgeable and willing parties. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount and the impairment loss is recognized in the profit or loss for the period. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash generating unit to which the asset belongs.

When an impairment loss subsequently reverses, the carrying amount of the asset (or cash generating unit) is increased to the revised estimate of its recoverable amount, but to an amount that does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

**Provisions**

i. Environmental rehabilitation provision

The Company recognizes liabilities for statutory, contractual, constructive or legal obligations, including those associated with the reclamation of exploration and evaluation assets and equipment, when those obligations result from the acquisition, construction, development or normal operation of the assets. Initially, a liability for an environmental

**VALENS GROWWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Notes to the Condensed Interim Statements  
For the Six Months Ended October 31, 2016  
(Unaudited-Expressed in Canadian Dollars)

---

**3. SIGNIFICANT ACCOUNTING POLICIES-continued**

**Provisions-continued**

**Environmental rehabilitation provision-continued**

rehabilitation obligation is recognized at its fair value in the period in which it is incurred if a reasonable estimate of cost can be made. The Company records the present value of estimated future cash flows associated with reclamation as a liability when the liability is incurred and increases the carrying value of the related assets for that amount. Subsequently, these capitalized asset retirement costs are amortized over the life of the related assets. At the end of each period, the liability is increased to reflect the passage of time (accretion expense) and changes in the estimated future cash flows underlying any initial estimates (additional rehabilitation costs). The Company recognizes its environmental liability on a site-by-site basis when it can be reliably estimated.

Environmental expenditures related to existing conditions resulting from past or current operations and from which no current or future benefit is discernible are charged to the profit and loss statement. The Company had no rehabilitation obligations as at October 31, 2016 or April 30, 2016.

ii. Other provisions

Provisions are recognized when the Company has a present obligation (legal or constructive) that has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the obligation. An amount equivalent to the discounted provision is capitalized within tangible fixed assets and is depreciated over the useful lives of the related assets. The increase in the provision due to passage of time is recognized as interest expense.

**Share-based compensation**

The Company grants stock options to acquire common shares of the Company to directors, officers, employees and consultants. An individual is classified as an employee when the individual is an employee for legal or tax purposes, or provides services similar to those performed by an employee.

The fair value of the options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the vesting period. The fair value is recognized as an expense with a corresponding increase in contributed surplus. When stock options are exercised, share capital is credited by the sum of the consideration paid and the related portion of share-based compensation previously recorded in contributed surplus. Consideration paid for the shares on the exercise of stock options is credited to share capital.

Share-based compensation arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of goods or services received. If the fair value of the goods or services received cannot be estimated reliably, the share-based payment transaction is measured at the fair value of the equity instruments granted at the date the Company receives the goods or the services.

**Income taxes**

Income tax on the profit or loss for the periods presented comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity.

Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at year end, adjusted for amendments to tax payable with regards to previous years.

### **3. SIGNIFICANT ACCOUNTING POLICIES-continued**

#### **Income taxes-continued**

Deferred tax is provided using the liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes, the initial recognition of assets or liabilities that affect neither accounting nor taxable profit, and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the financial position reporting date applicable to the period of expected realization or settlement.

A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized.

Additional income taxes that arise from the distribution of dividends are recognized at the same time as the liability to pay the related dividend.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis.

#### **Loss per share**

The Company presents basic earnings (loss) per share data for its common shares, calculated by dividing the net earnings (loss) available to common shareholders of the Company by the weighted average number of shares outstanding during the reporting period. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the weighted average shares outstanding are increased to include additional shares for the assumed exercise of stock options and warrants, if dilutive.

#### **Related party transactions**

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control. Related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

#### **Accounting standards not yet effective**

##### *IFRS 9, Financial Instruments – Classification and Measurement*

IFRS 9 is a new standard on financial instruments that will replace IAS 39, Financial Instruments: Recognition and Measurement.

IFRS 9 addresses classification and measurement of financial assets and financial liabilities as well as de-recognition of financial instruments. IFRS 9 has two measurement categories for financial assets: amortized cost and fair value. All equity instruments are measured at fair value. A debt instrument is at amortized cost only if the entity is holding it to collect contractual cash flows and the cash flows represent principal and interest. Otherwise it is at fair value through profit or loss. IFRS 9 is effective for annual periods beginning on or after January 1, 2018.

##### *IFRS 15, Revenue from Contracts with Customers*

**VALENS GROWWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Notes to the Condensed Interim Statements  
For the Six Months Ended October 31, 2016  
(Unaudited-Expressed in Canadian Dollars)

---

**3. SIGNIFICANT ACCOUNTING POLICIES-continued**

**Accounting standards not yet effective-continued**

IFRS 15 specifies how and when an IFRS reporter will recognize revenue as well as requiring such entities to provide users of financial statements with more informative and relevant disclosures. The standard provides a single, principles based five-step model to be applied to all contracts with customers.

IFRS 15 was issued in May 2014 and applies to an annual reporting period beginning on or after January 1, 2018.

*IFRS 11, Joint Arrangements*

IFRS 11 is amended to provide specific guidance on accounting for acquisition of an interest in a joint operation that is a business. The amended standard is effective for annual periods beginning on or after January 1, 2016.

*IAS 16, Property, plant and equipment and IAS 38 – Intangibles*

IAS 16 and IAS 38 were issued in May 2014 and prohibit the use of revenue-based depreciation methods for property, plant and equipment and limit the use of revenue-based amortization for intangible assets. These amendments are effective for annual periods beginning on or after January 1, 2016 and are to be applied prospectively.

The Company has initially assessed that there will be no material reporting changes as a result of adopting the above new standards; however, enhanced disclosure requirements are expected.

**4. INVESTMENT IN MKHS, LLC**

The Company has advanced \$2,329,408 (US\$1,756,313) to MKHS LLC (“MKHS”), a fully licensed, Arizona-based marijuana cultivation, extraction and medicinal dispensary business. MKHS supplies medical marijuana pursuant to the Arizona Medical Marijuana Act, operates two state-licensed “healing center” dispensaries and distributes its own in-house prepared, branded line of edibles, concentrates and extracts.

The Company’s advances were arranged to satisfy the terms and conditions of the Company’s initial Letter of Intent (the “LOI”) with MKHS dated October 30, 2015 and the superseding binding Letter of Commitment (the “LOC”) of November 24, 2015, whereby MKHS committed to be acquired by the Company through a share exchange transaction.

Under the LOC, the Company agreed to advance US\$200,000 secured and guaranteed under separate agreements and private arrangement with a Director and shareholder of the Company, US\$200,000 to be arranged by or on behalf of the Company or by one of its consultants via any combination of debt and/or equity, US\$450,000 to be arranged subsequent to the above described US\$400,000, either on a fully secured basis, acceptable to the lender, and/or through an interim equity raise by the Company, and US\$3.15 million to be raised through a mutually acceptable combination of equity and/or debt in due course.

Upon execution of the LOC, MKHS agreed to accrue \$50,000 payable to the Company as cost recoveries. \$10,000 was deemed earned upon execution, \$20,000 upon the Company receiving shareholder approval of the transaction (received April 26, 2016) and \$20,000 upon receiving conditional acceptance from the CSE. Amounts will be immediately payable if the agreement is terminated and the condition has been met. At October 31, 2016 \$30,000 (April 30, 2016 - \$30,000) was included in receivables.

An Operating Agreement (the “OA”) under a newly formed entity, MKV Ventures 1, LLC (“MKV1”), was entered into between MKHS and Westland Capital Advisors S.A. (“Westland”), whereby the funded expansion is separately administered and controlled. In the event that MKHS terminates the LOC between MKHS and the Company without grounds, or fails to execute a follow-on agreement whereby the Company acquires MKHS under the terms as substantially agreed upon, or MKHS fails to provide annual audited financial statements under IFRS to the Company,

**VALENS GROWWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Notes to the Condensed Interim Statements  
For the Six Months Ended October 31, 2016  
(Unaudited-Expressed in Canadian Dollars)

---

**4. INVESTMENT IN MKHS, LLC-continued**

and as a result the Company elects to terminate the LOC, MKHS' fifty percent membership interest in MKV1 shall be deemed transferred to the Company without the need for further documentation.

In the event the transaction between MKHS and the Company does not close for any other reason, MKHS shall be deemed to have transferred ten percent of its membership interest in MKV1 to the Company without the need for further documentation, and the Company shall be deemed admitted as a member under the OA and remain a member until such time as the Company has received distributions from the greater of twelve successful harvests or for two years of harvests from the additional funded greenhouse capacity.

The terms of the transaction will be more particularly set forth in a definitive agreement to be entered into by the two parties.

**5. EQUIPMENT**

	<b>Computer Equipment</b>
<b>Cost:</b>	
As at April 30, 2015	\$ 8,371
Additions	-
At October 31, 2015 and April 30, 2016	8,371
Additions	750
At October 31, 2016	\$ 9,121
<b>Depreciation:</b>	
At April 30, 2015	\$ 4,710
Charge for the period	719
October 31, 2015	5,429
Charge for the period	720
At April 30, 2016	\$ 6,149
Charge for the period	381
At October 31, 2016	\$ 6,530
<b>Net book value:</b>	
At April 30, 2016	\$ 2,222
At October 31, 2016	\$ 2,591

**VALENS GROWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Notes to the Condensed Interim Statements  
For the Six Months Ended October 31, 2016  
(Unaudited-Expressed in Canadian Dollars)

---

**6. SHARE CAPITAL AND CONTRIBUTED SURPLUS**

**Authorized share capital**

The Company is authorized to issue an unlimited number of common and preferred shares with no par value.

**Issued shares:**

On June 16, 2015 the Company closed a non-brokered private placement of 2,115,734 shares at a price of \$0.15 per share. The Company received cash proceeds of \$120,000, settled the promissory note payable of \$147,360 and settled accounts payable of \$50,000. The Company recognized a \$39,472 loss on the debt settlements which represented the difference between the trading price and the settlement price on the issuance date.

On September 22 and October 23, 2015 the Company closed two tranches of a non-brokered private placement of 944,444 units at a price of \$0.225 per unit. The Company received cash proceeds of \$192,750 and settled accounts payable of \$19,750. Each unit consisted of one common share and one common share purchase warrant, with each warrant entitling the holder to purchase one common share at a price of \$0.75 up to September 22 and October 23, 2017 respectively, subject to acceleration conditions.

On February 16, 2016 the Company closed a non-brokered private placement of 3,011,984 shares at a price of \$0.24 per share for gross proceeds of \$722,876 (US\$500,000), to meet the terms and conditions associated with the acquisition of MKHS (Note 4).

On May 17, 2016 the Company issued 2,233,333 shares at a price of \$0.12 to Westland Capital Advisors S.A. pursuant to the terms of the convertible debenture agreement.

On July 15, 2016 the Company completed a share consolidation, consolidating its issued and outstanding common shares on the basis of one (new) post consolidation share for each three (old) pre-consolidation shares. As at April 30, 2016, prior to accounting for the share consolidation, the Company had 27,255,586 common shares issued and outstanding. Retroactively accounting for the consolidation, the Company had 9,085,168 common shares issued and outstanding.

The exercise or conversion price and the number of common shares issuable under any of the Company's outstanding warrants and stock options have been proportionately adjusted to reflect the consolidation in accordance with their respective terms thereof. No fractional common shares were issued pursuant to the consolidation, and any fractional common shares that would otherwise be issued were rounded down or up to the nearest whole number.

**Warrants**

The Company's warrant transactions are summarized as follows:

	<b>October 31, 2016</b>		<b>April 30, 2016</b>	
	<b>Number of Warrants</b>	<b>Weighted Average Exercise Price \$</b>	<b>Number of Warrants</b>	<b>Weighted Average Exercise Price \$</b>
Balance, beginning of period	944,444	0.75	189,891	6.00
Issued	-	-	944,444	0.75
Expired	-	-	(189,891)	6.00
Balance, end of period	944,444	0.75	944,44	0.75

**VALENS GROWWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Notes to the Condensed Interim Statements  
For the Six Months Ended October 31, 2016  
(Unaudited-Expressed in Canadian Dollars)

---

**6. SHARE CAPITAL AND CONTRIBUTED SURPLUS-continued**

**Warrants-continued**

The following table summarizes the warrants outstanding as at October 31, 2016:

Warrants outstanding	Exercise price \$	Expiry date
622,222	0.75	September 22, 2017 <sup>(1)</sup>
322,222	0.75	October 22, 2017 <sup>(1)</sup>

- (1) The Company is entitled to accelerate the expiry date of all the outstanding \$0.75 warrants to the date that is 30 days following the date the Company issues a news release announcing that the published closing price of the common shares on the CSE has been equal or greater than \$0.90 for any 10 consecutive trading days after the statutory hold period.

**Stock options**

The Company has an incentive stock option plan which permits the Board of Directors of the Company to grant options to directors, employees and non-employees to acquire common shares of the Company at fair market value on the date of approval by the Board of Directors. A portion of the stock options vests at the end of the first quarter from the grant date and the balance vests over a period of up to five years from grant date.

The following table summarizes the changes in the outstanding stock options:

	October 31, 2016		April 30, 2016	
	Number of Options	Weighted Average Exercise Price \$	Number of Options	Weighted Average Exercise Price \$
Balance, beginning of the period	405,000	0.94	223,333	3.00
Granted	-	-	341,666	0.30
Expired/cancelled	-	-	(160,000)	2.44
Balance, end of period	405,000	0.94	405,000	0.94
Options exercisable, end of period	405,000	0.94	250,834	1.34



**VALENS GROWWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Notes to the Condensed Interim Statements  
For the Six Months Ended October 31, 2016  
(Unaudited-Expressed in Canadian Dollars)

---

**6. SHARE CAPITAL AND CONTRIBUTED SURPLUS-continued**

**Stock options-continued**

The following table summarizes the options outstanding as at October 31, 2016:

Options outstanding	Options exercisable	Exercise price \$	Expiry date
36,667	36,667	3.00	September 25, 2017
40,000	40,000	3.00	October 10, 2018
20,000	20,000	3.00	November 27-28, 2018
258,333	258,333	0.30	August 31, 2020
50,000	50,000	0.30	September 22, 2020
405,000	405,000		

The fair value of options granted is estimated using the Black-Scholes option pricing model with the following assumptions:

	October 31, 2016	April 30, 2016
Average dividend per share	-	-
Average forecasted volatility	176%	176%
Average risk-free interest rate	0.43%	0.43%
Average expected life	5 years	5 years
Fair value – weighted average of options issued	\$ 0.19	\$ 0.19

For the period ended October 31, 2016, the Company recorded share-based compensation expense with an offsetting increase to contributed surplus of \$6,650 (year ended April 30, 2016 - \$53,150).

**7. RELATED PARTY TRANSACTIONS**

During the period ended October 31, 2016, the Company entered into the following transactions with related parties, not disclosed elsewhere in these financial statements:

- i. During the period ended October 31, 2016, \$8,400 (October 31, 2015 - \$12,000) rent was paid or accrued to a company controlled by a family member of a director and officer of the Company.
- ii. As at October 31, 2016, \$19,762 (October 31, 2015-\$15,000) consulting fees were paid or accrued for services performed by a company controlled by a family member of a director of the Company.

**VALENS GROWWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Notes to the Condensed Interim Statements  
For the Six Months Ended October 31, 2016  
(Unaudited-Expressed in Canadian Dollars)

**7. RELATED PARTY TRANSACTIONS-continued**

Summary of key management personnel compensation is as follows:

	<b>For the six months ended October 31,</b>	
	<b>2016</b>	<b>2015</b>
Share-based compensation*	\$ 3,827	\$ 3,119
Consulting, management and directors' fees	\$ 97,500	\$ 97,500

\* The estimated fair value of the stock options granted during the year was determined using the Black-Scholes option pricing model.

Included in accounts payable and accrued liabilities as at October 31, 2016 was \$1,375,057 (April 30, 2016 - \$771,827) due to companies controlled by a family member of a director of the Company.

**8. CONVERTIBLE DEBENTURES**

On November 9, 2015 the Company completed the first tranche of a convertible debenture offering of 2,680 \$100 convertible debentures (collectively the "CDs") for proceeds of \$268,000 (US\$200,000). On January 21, 2016 the second tranche was completed raising a further \$363,500 (US\$250,000) to provide funds to meet the initial terms of the Company's LOC with MKHS.

Each \$100 CD entitles the debenture holder (the "Holder") thereof to convert into 833 common shares of the Company, for a period of up to six months (the "Maturity Date"). The CDs are non-interest-bearing, however should the investor fail to convert any or all CDs by the maturity date a bonus payment of up to US\$40,000 shall be payable to the Holder. All securities issued in connection with the offering are subject to a statutory hold period of four months plus a day from the date of distribution in accordance with applicable securities legislation.

	<b>Liability Component \$</b>	<b>Equity Component \$</b>
Balance, April 30, 2015	-	-
November 9, 2015 convertible debenture issuance	247,714	21,286
January 21, 2016 convertible debenture issuance	334,629	28,871
Accretion	36,918	-
Balance, April 30, 2016	618,261	50,157
Conversion of 2,680 CDs	(246,714)	(21,286)
Balance, October 31, 2016	371,547	28,871

On May 9, 2016 \$268,000 (US\$200,000) principal amount of the issued and outstanding \$100 CDs were exercised for conversion to 2,233,333 common shares of the Company.

On November 2, 2016 the remaining of the convertible debentures were exercised for conversion to 3,029,166 common shares of the Company.

The debentures were subscribed for by Westland, a non-arm's-length party to the Company. A director and the Company's Chairman and CEO is an officer of Westland.

**VALENS GROWORKS CORP.**  
(Formerly Genovation Capital Corp.)  
Notes to the Condensed Interim Statements  
For the Six Months Ended October 31, 2016  
(Unaudited-Expressed in Canadian Dollars)

**9. CAPITAL RISK MANAGEMENT**

The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the acquisition of accretive investment opportunities. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company defines capital that it manages as shareholders' equity (deficiency).

The Company has historically relied on the equity markets to fund its activities. Current financial markets are very difficult and there is no certainty with respect to the Company's ability to raise capital. The Company will continue to assess new projects and seek to acquire an interest in potentially accretive opportunities if it feels there is sufficient economic potential and if it has adequate financial resources to do so. Management reviews its capital management approach on an on-going basis and believes that this approach, given the relative size of the Company, is reasonable.

The Company currently is not subject to externally imposed capital requirements. There were no changes in the Company's approach to capital management. The Company currently has not paid any dividends to its shareholders.

**10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT**

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

- a. Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities
- b. Level 2 – inputs other than quoted prices that are observable for the asset or liability either directly or indirectly
- c. Level 3 – inputs that are not based on observable market data

	Financial assets at fair value			October 31, 2016
	Level 1	Level 2	Level 3	
Fair value through profit and loss financial asset				
Cash and cash equivalents	\$ 8,912	-	-	\$ 8,912
<b>Total financial assets at fair value</b>	<b>\$ 8,912</b>	<b>-</b>	<b>-</b>	<b>\$ 8,912</b>

	Financial assets at fair value			April 30, 2016
	Level 1	Level 2	Level 3	
Fair value through profit and loss financial asset				
Cash and cash equivalents	\$ 70,720	-	-	\$ 70,720
<b>Total financial assets at fair value</b>	<b>\$ 70,720</b>	<b>-</b>	<b>-</b>	<b>\$ 70,720</b>

The fair values of the Company's receivables, due from related parties, advances receivable, accounts payable and accrued liabilities and promissory note payable approximate their carrying values due to their short term nature and are classified as a Level 1 measurement.

The Company is exposed to varying degrees to a variety of financial instrument related risks. The Board approves and monitors the risk management processes, inclusive of counterparty limits, controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows:

Credit risk

Credit risk is the risk of loss associated with counterparty's inability to fulfill its payment obligations. The Company believes it has no significant credit risk.

## **VALENS GROWWORKS CORP.**

(Formerly Genovation Capital Corp.)

Notes to the Condensed Interim Statements

For the Six Months Ended October 31, 2016

(Unaudited-Expressed in Canadian Dollars)

---

### **10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT-continued**

#### Liquidity risk

Liquidity risk is the risk that the Company will not be able to pay financial instrument liabilities as they come due. The Company currently does not have sufficient capital in order to meet short-term business requirements, after taking into account the Company's holdings of cash. The Company's cash is invested in bank accounts which are available on demand.

#### Market risk

The only significant market risk exposure to which the Company is exposed is interest rate risk. The Company's bank account earns interest income at variable rates. The fair value of its portfolio is relatively unaffected by changes in short-term interest rates. The Company's future interest income is exposed to short-term rates.

#### Foreign currency risk

The Company is exposed to foreign currency risk on fluctuations related to cash and accounts payable and accrued liabilities that are denominated in Canadian Dollars (CDN), and US Dollars (USD).

#### Price risk

The Company is exposed to price risk with respect to commodity and equity prices. Equity price risk is defined as the potential adverse impact on the Company's earnings due to movements in individual equity prices or general movements in the level of the stock market. Commodity price risk is defined as the potential adverse impact on earnings and economic value due to commodity price movements and volatilities. The Company closely monitors commodity prices of raw materials, individual equity movements, and the stock market to determine the appropriate course of action to be taken by the Company.

### **11. CONTINGENT LIABILITY**

On July 16, 2014 a Civil Lawsuit was filed with the Supreme Court of British Columbia concerning a US\$50,000 payment made towards plaintiffs' participation in the Company's Indonesian oil field project. The claim resulted from the plaintiffs' desire to fund and participate in work-overs of onshore multi-reservoir oil fields, a project that was never completed. The Company filed a response and counterclaim on August 18, 2014 and sought to hold discoveries in June 2015, to which the plaintiffs failed to reply. Given the dormant nature of the claim, the Company reversed the accrued US\$50,000 from accrued liabilities related to the claim in the year ended April 30, 2016, and has not accrued for interest or damages.

### **12. SUBSEQUENT EVENTS**

On November 2, 2016 the Company announced the acquisition (the "Transaction") of all the issued and outstanding shares of Valens Agritech Ltd. ("VAG") by way of a share exchange agreement dated October 31, 2016, (the "SEA"). Valens is a privately held biotechnology company based in the Okanagan Valley of British Columbia, focused on the cannabis cultivation and research business, with assets and improvements that include a state-of-the-art 17,000 square foot research and development facility located on a small acreage in Kelowna.

VAG has expended over \$2.7 million to satisfy the stringent security requirements for a Controlled Drugs and Substances Dealer's Licence (including the activities of cultivation, production (extraction), packaging, possession, sale, transportation, delivery and research), and is currently awaiting final inspection by the Regional Inspectorate of the Office of Controlled Substances, Health Canada, scheduled for the week of January 9, 2017.

Pursuant to the terms of the SEA, the Company is issuing to the shareholders of VAG (the "VAG Shareholders") an aggregate of 36 million common shares of the Company ("Transaction Shares") and finders' fees ("Finder Shares") totaling 675,000 common shares at closing of the Transaction, subject to a combination of milestone vesting criteria, regulatory escrow provisions and a voluntary pooling agreement, over a period of 36 months.

## **VALENS GROWORKS CORP.**

(Formerly Genovation Capital Corp.)

Notes to the Condensed Interim Statements

For the Six Months Ended October 31, 2016

(Unaudited-Expressed in Canadian Dollars)

---

### **12. SUBSEQUENT EVENTS-*continued***

The Transaction is a fundamental change under the policies of the Canadian Securities Exchange (the "CSE"). The Company's Form 2A Listing Statement dated October 31, 2016 is available under the Company's SEDAR and CSE profiles, providing further details concerning the Transaction and the business of the combined company.

On November 2, 2016 Westland Capital Advisors S.A. ("Westland") exercised all remaining issued and outstanding Convertible Debentures totaling \$363,500 (US\$250,000) concurrently with the closing of the Transaction, into 3,029,166 common shares of the Company.

On November 24, 2016 the Company changed its name from Genovation Capital Corp. to Valens GroWorks Corp. and commenced trading under the new name and trading symbol "VGW" following the issue of the CSE's bulletin to dealers. The Company's new CUSIP number is 91913D106 and the new ISIN is CA91913D1069. There is no change to the Company's share structure.

On November 30, 2016 the Company announced a non-brokered private placement of up to 2,000,000 units (the "Units") at a price of \$0.65 per Unit for gross proceeds of up to \$1,300,000 (the "Offering"). The net proceeds from the Offering will be used by the Company for security upgrades to the Company's R&D facility in Kelowna and general corporate purposes, including the partial repayment of related party loans and accrued payables.

Each Unit will consist of one common share of the Company (a "Common Share") and one-half of a Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of \$1.15 for a period of 12 months from the closing of the Offering, subject to the acceleration provision described below. The Units will be made available by way of prospectus exemptions in Canada and in such other jurisdictions as the Company may agree where the Units can be issued on a private placement basis, exempt from any prospectus, registration, or other similar requirements.

The Company will be entitled to accelerate the expiry date of the Warrants to the date that is 30 days following the date the Company issues a news release announcing that the published closing price of the Common Shares on the Canadian Securities Exchange (the "CSE") has been equal to or greater than \$1.65 for ten consecutive trading days after the hold period on the Common Shares has expired.

On November 30, 2016 the Company granted incentive stock options to certain directors, officers and consultants of the Company to purchase up to 2.55 million common shares of the Company at a price of \$0.65 per common share. The stock purchase options are exercisable on or before December 1, 2021 and vest in stages over the course of a year with 25% to vest immediately and a further 25% of the options to vest in each three-month period thereafter. The stock options are being granted pursuant to the terms of the Company's stock option plan and are subject to regulatory approval.